rosuvastatin

Ligand id: 2954

Name: rosuvastatin

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rosuvastatin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 149.3
Molecular weight 481.17
XLogP 2.69
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of primary hyperlipidemia, mixed dyslipidemia and hypertriglyceridemia.
The US FDA approved marketing of the first generic version of rosuvastatin calcium in May 2016.
Mechanism Of Action and Pharmacodynamic Effects
Competitive inhibitor of HMG-CoA reductase, the enzyme catalysing the rate-limiting step of cholesterol synthesis. Acting primarily in the liver, rosuvastatin decreases hepatic cholesterol concentrations. For a complete overview of the mechanism of action of this drug, please see the entry on DrugBank linked to from this ligand page.
External links